Butein suppresses the expression of nuclear factor-kappa B-mediated matrix metalloproteinase-9 and vascular endothelial growth factor in prostate cancer cells.
3,4,2',4'-Tetrahydroxychalcone (butein) has potent anti-inflammatory, anti-cancer and anti-fibrogenic effects. However, little is known about the mechanism by which butein inhibits metastasis and invasion. This study aimed to investigate the effects of butein on the expression of matrix metalloproteinase (MMP-9) and vascular endothelial growth factor (VEGF) in human prostate cancer cells. Butein in vitro resulted in a moderate inhibition of cell proliferation and viability through G(2)/M phase arrest. We also analyzed the effect of butein on the activities of nuclear factor-kappa B (NF-κB)-regulated MMP-9 and VEGF since they are prominently involved in the processes of tumor cell invasion and metastasis. Our results in vitro showed that butein attenuates VEGF and MMP-9 activities via the suppression of NF-κB activity. Furthermore, butein repressed the expression of VEGF and MMP-9 induced by treatment with tumor necrosis factor-α and phorbol-12-myristate-13-acetate. Taken together, these data suggest that a blockade of NF-κB activity by butein inhibits invasion and angiogenesis in prostate cancer cells.
Moon
Dong-Oh
DO
Laboratory of Immunobiology, Department of Marine Life Sciences, Jeju National University, Jeju 690-756, Republic of Korea.
Choi
Yung Hyun
YH
Moon
Sung-Kwon
SK
Kim
Wun-Jae
WJ
Kim
Gi-Young
GY
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D047188:Chalcones / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000187:drug effects / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000187:drug effects / Q000378:metabolism; D009361:Neoplasm Invasiveness / Q000517:prevention & control; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D047188:Chalcones; D016328:NF-kappa B; D042461:Vascular Endothelial Growth Factor A; C040918:butein; D020780:Matrix Metalloproteinase 9